Natural killer cells and cancer

Cancer

Volumn 77, Issue 7, 1996, Pages 1226-1243

  Brittenden, Julie ^a   Heys, S D ^a   Ross, J ^a   Eremin, O ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

cancer; chemotherapy; immune biological modifiers; natural cytotoxicity; radiotherapy; surgery

Indexed keywords

ALPHA INTERFERON; ANTIMITOTIC AGENT; ASPARAGINASE; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DOXORUBICIN; ESTRADIOL; GAMMA INTERFERON; GLYCOPROTEIN P; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; PICIBANIL; POLYADENYLIC POLYURIDYLIC ACID;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CYTOTOXICITY; ETIOLOGY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 0029971671     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1226::AID-CNCR2>3.0.CO;2-G     Document Type: Review

References (266)

1. Trincheri G. Biology of natural killer cells. Adv Immunol 1989;47:187-375.
2. Inveraldi L, Witson JC, Fuad SA, Winkler-Pickett RT, Ortaldo JR, Balch FH. CD3 negative "small agranular lymphocytes" are natural killer cells. J Immunol 1991;146:4948-52.
3. Ortaldo JR, Winkler-Pickett R, Kopp W, Kawasaki A, Nagashima K, Okumara K, et al. Relationship of large and small CD3-CD56+ lymphocytes mediating NK-associated activities. J Leuko Biol 1992;52:287-95.
4. Liao NS, Bix M, Zijistra M, Jaenisch R, Raulet DH. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
5. Kalhofer FM, Hunziker R, Reichlin A, Margulies DH, Yokoyama WM. Host MHC class I molecules modulate in vivo expression of a NK cell receptor. J Immunol 1994;153:2407-16.
6. Ritz J. The role of natural killer cells in immune surveillance. N Engl J Med 1989;320:1748-9.
7. Hansson M, Kiessling R, Anderson B. Human fetal thymus and bone marrow contain target cells for natural killer cells. Eur J Immunol 1981;11:8-12.
8. Einhorn S, Anderbring E. Human peripheral blood monocytes are susceptible to interferon-activated natural killer cells. J Clin Lab Immunol 1985;16:197-9.
9. Djeu JY, Blanchard DK. Lysis of human monocytes by lymphokine activated killer cells. Cell Immunol 1988;111:55-6.
10. Grimm E, Grimm A, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
11. Trincheri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin-2. J Exp Med 1984;160:1147-69.
12. Herberman RB. Lymphokine-activated killer cell activity. Immunol Today 1987;8:178-80.
13. Dianzani U, Zarcone D, Pistoni V, Grossi CE, Pileri A, Massaia M. CD8+-CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. Eur J Immunol 1989;19:1037-44.
14. Philipps JH, Lanier LL. Dissection of the lymphokine activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164:814-25.
15. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
16. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988;42:181-211.
17. Suzuki N, Suzuki T, Engleman EG. Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells. J Exp Med 1991;173:1451-61.
18. Lanier LL, Le AM, Civin CI, Loken MR, Philips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic lymphocytes. J Immunol 1986;136:4480.
19. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983;130:2947-51.
20. Perussia B, Starr S, Abraham S, Fanning V, Trincheri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 1983;130:2133-41.
21. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988;141:3478-85.
22. Lanier LL, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983;131:1789-96.
23. Abo T, Miller CA, Balch CM. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults. Eur J Immunol 1984;14:616-23.
24. Timonen T, Patarroyd M, Gahmberg CG. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol 1988;141:1041-6.
25. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta R. Human natural killer cells: origin, clonality, specificity and receptors. Adv Immunol 1994;155:341-80.
26. Sconocchoia G, Titus JA, Segal DM. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J Immunol 1994;153:5473-81.
27. Lotzova E. Definition and functions of natural killer cells. Nat Immun 1993;12:169-76.
28. Lozzio CB, Lozzio BB. Cytotoxicity of a factor isolated from human spleen. J Natl Cancer Inst 1973;50:535-8.
29. Jondal M, Pross HF. Surface markers on human B- and T-lymphocytes. VI. Cytotoxicity against cell lines as functional markers for lymphocyte subpopulations. Int J Cancer 1975;15:596-605.
30. Pross HF, Callewaert D, Rubin P. Assays for NK cell cytotoxicity - their values and pitfalls. In: Lotozova E, Herberman RB. Immunology of natural killer cells. Florida: CRC Press, 1986;1:1-20.
31. Pross H, Maroun JA. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 1984;68:235-49.
32. Dye JF, Somers SS, Guillou P. Simplified quantification of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. J Immunol Methods 1991;138:1-13.
33. Chang L, Gusewitch GA, Chritton DB, Folz JC, Lebeck LK, Nehlsen-Cannarella SL. Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 1993;166:45-54.
34. Hatam L, Schuval S, Bonagura VR. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry 1994;16:59-68.
35. Papadopoulos NG, Dedoussis GV, Spanakos AD, Gritzapis AD, Baxevanis CN, Papamichail M. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 1994;177:101-11.
36. Young JDE, Cohn ZA. Cellular and humoral mechanisms of cytotoxicity: Structural and functional analogies. Adv Immunol 1987;41:269-331.
37. Ortaldo JR, Hiserodt JC. Mechanisms of target killing by natural killer cells. Curr Opin Immunol 1989;2:39-42.
38. Hiserodt JC. Some thoughts on the cytolytic mechanisms of natural killer lymphocytes. Cancer Cells 1991;3:530-2.
39. Y Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol 1995;7:110-20.
40. Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 1989; 169:1373-89.
41. Karlhofer FM, Yokoyama WM. Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2 activated NK cells possess additional specific stimulation pathways. J Immunol 1991;146:3662-73.
42. Lanier LL, Chang C, Phillips JH. Human NKR-P1A. Adisulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417-28.
43. Ryan JC, Niemi EC, Goldfien RD, Hiserodt JC, Seaman WE. NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium. J Immunol 1991;147:3244-50.
44. Yokoyama WM. Recognition structures on natural killer cells. Curr Opin Immunol 1993;5:67-73.
45. Giorda R, Weisberg EP, IP TK Trucco M. Genomic structure and strain-specific expression of the natural killer receptor NKR-P1. J Immunol 1992;149:1957-63.
46. Karlhofer FM, Hunziker R, Reichlin A, Margulies DH, Yokoyama WM. Host MHC class I molecules modulate in vivo expression of a natural killer cell receptor. J Immunol 1994;153:2407-16.
47. Roth C, Kourilsky P, Djcius DM. Ly-49-independent inhibition of natural killer cell-mediated cytotoxicity by a soluble major histocompatibility complex class I molecule. Eur J Immunol 1994;24:2110-4.
48. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class-I protected cells in NK clones displaying different specificities. J Exp Med 1993;178:597-604.
49. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994;180:537-43.
50. Carpen O, Saksela A. Directed exocytosis in the NK cell-mediated cytotoxicity. A review. Nat Immun Cell Growth Regulation 1988;7:1-12.
51. Pertussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol 1991;3:49-55.
52. Squier MKT, Cohen JJ. Cell-mediated cytotoxic mechanisms. Curr Opin Immunol 1994;1:447-52.
53. Rabinowich H, Herberman RB, Whiteside TL. Differential effects of IL-12 and IL-2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993;152:481-91.
54. Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, et al. Enhancing effects of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol 1993;23:1826-30.
55. Trincheri G. Interleukin-12: a cytokine produced by antigen presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes [review]. Blood 1994;84:4008-27.
56. Lotzova E, Savary CA, Champlin RE. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol 1993;150:5263-9.
57. Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR-primitive progenitors in long-term bone marrow culture. Blood 1992;80:2182-7.
58. Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+NK progenitor. Blood 1994;83:2594-601.
59. Tjonnfyord GE, Steen R, Veiby OP, Egeland T. Thymic stromal cells support differentiation of natural killer cells from CD34+ bone marrow cells in vitro. Eur J Haematol 1995;54:46-50.
60. Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994;569-76.
61. Fox RI, Fong S, Tsoukas C, Vaughan J. Characterization of recirculating lymphocytes in rheumatoid arthritis patients: Selective deficiency of natural killer cells in thoracic duct lymph. J Immunol 1984;132:2883-7.
62. Blue ML, Levine H, Daley JF, Craig KA, Schlossman SF. Development of natural killer cells in human thymocyte culture; regulation by accessory cells. Eur J Immunol 1987; 17:669-73.
63. Sancho L, de la Hera A, Casas J, Vaquer S, Martinez C, Alvarez-Mon M. Two different maturational stages of natural killer lymphocytes in human newborn infants. J Pediatr 1991;119:446-54.
64. Krishnaraj R, Blandford G. Age associated alterations in human natural killer cells. 1. Increased activity as per conventional and kinetic analysis. Clin Immunol Immunopathol 1987;45:260-85.
65. Pross HF, Baines MG. Studies of human natural killer cells. 1. In vivo parameters affecting normal cytotoxic function. Int J Cancer 1982;29:383-90.
66. Tilden AB, Grossi CE, Itoh K, Cloud GA, Dougherty PA, Balch CM. Subpopulations analysis of human granular lymphocytes: Associations with age, gender and cytotoxic activity. Nat Immun Cell Growth Regul 1986;5:90-9.
67. Krishnaraj R, Blandford G. Age associated alterations in human natural killer cells. 2. Increased frequency of selective NK subsets. Cell Immunol 1988;114:137-48.
68. Welsh RM. Regulation of virus infections by natural killer cells: A review. Nat Immun Cell Growth Regul 1986;6:169-99.
69. Herberman RB, Ortaldo JR. Natural killer cells: Their role in defenses against disease [review]. Science 1981;214:24-30.
70. Talmadge IE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumor growth and metastasis in beige mice. Nature 1980;284:622-3.
71. Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol 1981;127:1754-8.
72. Barlozzari T, Leonhardt I, Wiltrout RH, Herberman RB, Reynolds CW. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 1985;134:2783-9.
73. Gorelick E, Wiltrout RH, Okmura K, Habu S, Herberman RB. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 1982;30:107-12.
74. Okumar K, Habu S, Kasai M. The role of NK cells in resistance of in vivo tumors. Adv Exp Med Biol 1982;155:635-44.
75. Hanna N. Inhibition of experimental tumor metastasis by selective activation of natural killer cells. Cancer Res 1982;42:1337-42.
76. Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: Involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol 1983;131:1024-7.
77. Roder JC, Halitosis T, Klein M, Korec S, Jett J, Ortaldo J, et al. A new immunodeficiency disorder in humans involving NK cells. Nature 1980;284:553-5.
78. Sullivan JL, Bryon KS, Brewster FE, Purtilo DT. Deficient natural killer cell activity in X-linked lymphoproliferative syndrome. Science 1980;210:543-5.
79. Gui XE, Charles R, Rinaldo JR, Monto HO. Natural killer cell activity in renal transplant recipients receiving cyclosporine. Infect Immun 1983;41:965-70.
80. Hersey P, Edwards A, Honeyman M, McCarthy WH. Low natural killer cell activity in familial melanoma patients and their relatives. Br J Cancer 1979;40:113-22.
81. Sibbitt WL, Bankhurst AD, Jumonville AJ, Saiki JH, Saiers JH, Doberneck RC. Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 1984;44:852-6.
82. Mickel RA, Kessler DJ, Taylor JMG, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988;48:5017-22.
83. Kumazawa H, Hess M. Influence of serum derived from patients with head and neck cancer on natural killer cell activity. Oncology 1991;48:372-6.
84. Lakhdar M, Oueslati R, Ellouze R, Thameur H, Cammoun M, Khedhiri N, et al. High Interferon titre and defective NK-cell activity in the circulation of nasopharyngeal carcinoma patients. Int J Cancer 1989;43:543-8.
85. Schantz SP, Campbell BH, Guillamondegul OM. Pharyngeal carcinoma and natural killer cell activity. Am J Surg 1986;152:467-4.
86. LeFever AV, Funahashi A. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma. Cancer Res 1991;51:5596-601.
87. Introna M, Allavena P, Biondi A, Colombo N, Villa A, Mantovani A. Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ. J Natl Cancer Inst 1983;70:21-6.
88. Vaquer S, Jorda J, Lopez de la Osa E, Alvarez de los Heros J, Lopez-Garcia N, Alvarez de Mon M. Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1990;36:90-2.
89. Morita T, Tokue A, Minato N. Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer. Cancer Immunol Immunother 1990;32:191-4.
90. Lahat N, Alexander B, Levin DR, Moskovitz B. The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol Immunother 1989;28:207-12.
91. Chuang WL, Liu HW, Chang WY. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 1990;65:926-30.
92. Funa K, Nilsson B, Jacobson G, Aim GV. Decreased natural killer cell activity and interferon production by leucocytes in patients with adenocarcinoma of the pancreas. Br J Cancer 1984;50:231-3.
93. Tsutsi S, Moirta M, Kuwano H, Matsuda H, Mori M, Okamura S, et al. Influence of preoperative treatment and surgical operation on immune function of patients with oesophageal carcinoma. J Surg Oncol 1992;49:176-81.
94. Cunningham-Rundles S, Flippa DA, Braun DW, Antonelli P, Ashikari H. Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells of breast cancer in women. J Natl Cancer Inst 1981;67:585-90.
95. Steinhauer EH, Doyle AT, Reed J, Kadish AS. Defective natural cytotoxicity in patients with cancer: normal number of effector cells but increased recycling capacity in patients with advanced disease. J Immunol 1982;5:2255-9.
96. Vose BM, Vanky F, Argov S, Klein E. Natural cytotoxicity in man; activity of lymph node and tumor-infiltrating lymphocytes. Eur J Immunol 1977;7:753-7.
97. Aparicio-Pages NM, Verspaget HW, Pena SA, Lamers CBHW. Impaired local natural killer cell activity in human colorectal carcinomas. Cancer Immunol Immunother 1989;28:301-4.
98. Pislarasu M, Opriou A, Tarana D, Herberman RB, Sulica A. Modulation of natural killer cell activity by serum from cancer patients: Preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer. Cancer Res 1988;48:2596-603.
99. Wustow TPU, Zenner H-P. Natural killer cell activiry in patients with carcinoma of the larynx and hypopharynx. Laryngoscope 1985;95:1391-9.
100. Schantz SP, Liu FJ. An immunological profile of young adults with head and neck cancer. Cancer 1989;64:1232-7.
101. Eremin O, Ashby J, Stephens JP. Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 1978;21:35-41.
102. Kadish AS, Doyle AT, Steinhauer EH, Ghossen NA. Natural cytotoxicity and Interferon production in human cancer: deficient natural killer activity and normal Interferon production in patients with advanced disease. J Immunol 1981;127:1817-22.
103. Pross HF, Baines MG. Spontaneous human lymphocyte mediated cytotoxicity against tumor cells. The effect of malignant disease. Cancer 1976;18:593-604.
104. Tagasugi M, Ramseyer A, Takasugi J. Decline of natural non-selective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 1977;37:413-18.
105. Seltzer V, Doyle A, Kadish AS. Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon. Gynecol Oncol 1983;15:340-9.
106. Monson JRT, Ramsden CW, Giles GR, Brennan TG, Guillou PJ. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer. Gut 1987;28:1420-5.
107. Pross HG, Baines MG. Alterations in natural killer cell activity in tumor bearing hosts. In: Lotzova E, Herberman R, Editors. Immunobiology of natural killer cells. Boca Raton: CRC Press, 1986;1:57-78.
108. Villa ML, Ferrario E, Bergamasco E, Bozzetti F, Cozzaglio L, Clerici E. Reduced natural killer cell activity and IL-2 production in malnourished cancer patients. Br J Cancer 1991;63:1010-4.
109. De AK, Jhaver KG, Kamat MR, Nadkami JJ. Lymphokine activated killer cells and interleukin-2 production in patients with cervical carcinoma. Neoplasma 1991;38:493-9.
110. Sone S, Kunihige E, Fawzy F, Yanagawa H, Nii A, Maeda K-I, et al. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients. Jpn J Cancer Res 1991;82:716-23.
111. Dunlap NE, Lane VG, Cloud GA, Tilden AB. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma. Cancer 1990;66:1499-504.
112. Balch CM, Itoh K, Tilden AB. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 1985;98:151-7.
113. Strayer DR, Carter W, Mayberry S, Pequignot E, Brodsky I. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 1984;44:370-4.
114. Nakajuma H, Mizushima N, Kanai K. Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver. Jpn J Clin Oncol 1987;17:327-32.
115. Hersey P, Edwards A, Milton GW, McCarthy WH. No evidence for an association between natural killer cell activity and prognosis in melanoma patients. Nat Immun Cell Growth Regul 1984;3:1-6.
116. Schantz SP, Savage HE, Racz T, Taylor DL, Sachs PG. Natural killer cells and metastases from pharyngeal carcinoma. Am J Surg 1989;158:361-6.
117. Schantz SP, Ordonez NG. Quantification of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer. Nat Immun Cell Growth Regul 1993; 10:278-88.
118. Pross HF, Lotzova E. Role of natural killer cells in cancer. Nat Immun 1993;12:279-92.
119. Tartter PA, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-8.
120. Vose BM, Moore M. Suppressor cell activity of lymphocytes infiltrating human Lung and breast tumors. Int J Cancer 1979;24:579-85.
121. Eremin O, Coombes RRA, Ashby J. Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity. Br J Cancer 1981;44:166-76.
122. Niitsuma M, Golub SH, Edelstein R, Holmes EC. Lymphoid cells infiltrating human pulmonary tumors: effect of intralesional BCG injection. J Natl Cancer Inst 1981;67:997-1003.
123. Faure F, Triebel F, Hercend T. MHC-unrestricted cytotoxicity. Immunol Today 1990;11:108-9.
124. Parmiani G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 1990;11:113-5.
125. Moy PM, Holmes EC, Golub SH. Depression of natural killer cytotoxicity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 1985;45:57-60.
126. Holmes EC. Immunology of tumor infiltrating lymphocytes. Ann Surg 1985;201:158-9.
127. Balch CM, Riley LB, Bae YL, Salmeron MA, Platsoucas CD, von Eschenbach A, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
128. Chin Y, Yanseens I, Vandepirre J, Vandenbrande J, Opdebeek L, Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1993; 12:1463-6.
129. Pisani RJ, Kco CJ, Wold LE, McKean DI. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer. Am J Clin Pathol 1989;92:435-46.
130. Staren ED, Economou SG, Harris JE, Braum DP. Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients. Cancer 1989;64:2238-42.
131. Rosenberg SA, Spies P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986;233:205-8.
132. Eremin O, Ashby J, Franks D. Killer cell NK activity in human normal lymph node and inflammatory lymph node. Int Arch Allergy 1977;54:210-20.
133. Karimine N, Arinaga S, Inoue H, Nanbara S, Ueo H, Akiyoshi T. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients. Clin Exp Immunol 1994;96:484-90.
134. Tatake RJ, Krishnan HN, Rao RS, Fakih AR, Gangal SG. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Int J Cancer 1989;43:563-6.
135. Yano T, Yasamoto K, Nomoto K. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer. Eur J Cancer Clin Oncol 1987;15:201-8.
136. Rubbert A, Manger B, Lang N, Kalden JR, Platzer E. Functional characterization of tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer 1991;49:25-31.
137. Mainou-Fowler T, Eremin O. Tumor-associated proliferative responses in vitro of regional lymph nodes draining solid cancers in man. Cancer Immunol Immunother 1989;30:300-6.
138. Serrano R, Yiangou Y, Solano R, Sachs JA, Pena J. Isolation of a novel tumor protein that induces resistance to natural killer cell lysis. J Immunol 1990;145:3516-23.
139. Guillou PJ, Ramsden CW, Somers SS, Sedman PC. Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumor cell lines. Br J Cancer 1989;59:515-21.
140. Pelton JJ, Taylor DD, Fowler WC, Taylor CG, Carp NZ, Weese JL. Lymphokine-activated killer cell suppressor factor in malignant effusions. Arch Surg 1991;126:476-80.
141. Itoh K, Tilden AB, Balch CM. Role of interleukin-2 and a serum suppressor factor on the induction of activated killer (LAK) cells cytotoxic for autologous human melanoma cell lines. Cancer Res 1985;45:3173-8.
142. Park KGM, Heys SD, Murray JB, Hayes PD, Ashby JA, Eremin O. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity. Cancer Immunol Immunother 1992;35:53-8.
143. Kumazawa H, Hess M. Influence of serum derived from patients with head and neck cancer on natural killer cell activity. Oncology 1991;48:372-6.
144. Marubayashi M, Solano R, Ramirez R, Aranda E, Galan F, Pena J. Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). Br J Cancer 1991;63:893-6.
145. Griffith CDM, Penning C, Rees RC, Rogers K. Depression of human natural killer lymphocyte activity after exposure to peripheral and tumor draining venous plasma of cancer patients [abstract]. Br J Surg 1984;71:911.
146. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
147. Nakagomi H, Peterson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-2.
148. Foulds S, Wakefield CH, Giles M, Gillespie J, Dye JF, Guillou PJ. Expression of a suppressive p15E-related epitope in colorectal and gastric cancer. Br J Cancer 1993;68:610-6.
149. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993;72:491-501.
150. Letessier EM, Sacchi M, Johnson JT, Herberman RB, Whiteside TL. The absence of lymphoid suppressor cells in tumor involved lymph nodes of patients with head and neck cancer. Cell Immunol 1990;130:446-58.
151. Synderman CH, Heao DS, Johnson JT, d'Amico F, Barnes L, Whiteside TL. Functional and phenotypic analysis of lymphocytes in head and neck cancer. Arch Otolaryngol Head Neck Surg 1991;117:899-905.
152. Ebihara T, Koyama S, Fukao K, Osuga T. Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma. Cancer Immunol Immunother 1989;28:218-24.
153. Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, et al. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J Exp Med 1987;166:303-18.
154. Cole WH, Humphrey L. Need for immunological stimulators during immunosuppression produced by major cancer surgery. Ann Surg 1985;202:9-20.
155. Jensen LS, Andersen AJ, Christiansen PM, Hokland P, Juhl C, Madsen G, et al. Post-operative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79:513-6.
156. Tonnesen E, Mickley H, Grunnet N. Natural killer cell activity during premedication, anaesthesia and surgery. Acta Anaesthesiol Scand 1983;27:238-41.
157. Griffin CD, Rees RC, Platts A, Jeremy A, Peel J, Rogers K. The nature of enhanced natural killer lymphocyte cytotoxicity during anaesthesia and surgery in patients with benign disease and cancer. Ann Surg 1984;200:753-8.
158. Lennard TW, Shenton BK, Borozotta A, Donelly PK, White M, Gerrier LM, et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985;72:771-6.
159. Nielson HJ. Detrimental effects of perioperative blood transfusions. Br J Surg 1995;82:582-7.
160. Uchida A, Kolb R, Micksche M. Generation of suppressor cells for natural killer cell activity in cancer patients after surgery. J Natl Cancer Inst 1982;68:735-41.
161. McCulloch PG, MacIntyre A. Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg 1993;80:1005-7.
162. Sedman PC, Ramsden CW, Brennan TG, Glies GR, Guillou PJ. Effects of low dose perioperative interferon on the surgically induced suppression of anti-tumor immune response. Br J Surg 1988;75:976-81.
163. Nichols PH, Ramsden CW, Ward U, Trejdosiewicz LK, Ambrose NS, Primrose JN, et al. Peri-operative modulation of cellular immunity in patients with colorectal cancer. Clin Exp Immunol 1993;94:4-10.
164. Deehan DJ, Heys SD, Ashby J, Eremin O. Interleukin-1 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Surg Oncol 1995;21:16-22.
165. Lange PH, Hekmat K, Bosl G, Kennedy BJ, Fraley EE. Accelerated growth of testicular cancer after cytoreductive therapy. Cancer 1980;45:1498-506.
166. Lundy J, Lovett EJ, Wolinsky SM, Conran P. Immune impairment and metastatic tumor growth. The need for an immunorestorative drug as an adjunct to surgery. Cancer 1979;43:945-51.
167. Bloom HJG. Hormone induced and spontaneous regression of metastatic renal cancer. Cancer 1973;32:1066-71.
168. Tartter PI, Martnelli G, Steinberg B, Barron D. Changes in peripheral T-cell subsets and natural killer cytotoxicity in relation to colorectal cancer surgery. Cancer Detect Prev 1986;9:359-64.
169. Nichols PH, Ramsden CW, Ward U, Sedman PC, Primrose JN. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer. Cancer Res 1992;52:5765-9.
170. Lacour J, Lacour F, Spira A, Michelson M, Petit J-Y, Delage G, et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomized trial. BMJ 1984;288:589-92.
171. Khan AL, Richardson S, Drew J, Larsen F, Campbell M, Ashby J, et al. Peri-operative immunomodulation by polyadenylic-polyuridylic acid. Eur J Surg Oncol 1994;20:266-7.
172. Lee YC, Luh SP, Wu RM, Lee CJ. Adjuvant immunotherapy with intrapleural streptococcus pyogenes [OK-432] in lung cancer patients after resection. Cancer Immunol Immunother 1994;39:269-74.
173. Maehara Y, Inutsuka S, Takeuchio H, Baba H, Kusumoto H, Sugimachi K. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer Chemother Pharmacol 1993;33:171-5.
174. Sugimachi K, Maehara Y, Akazawa K, Kondo Y, Kunii Y, Kitamura M, et al. Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study. Cancer Chemother Pharmacol 1994;33:366-370.
175. Hanna N, Schneider M. Enhancement of tumor metastasis and suppression of natural killer cell activity by β-estradiol treatment. J Immunol 1983;130:974-80.
176. Seaman WE, Blackman MA, Gindhart TD, Roubina JR, Loeb JM, Talal N. β-Estradiol reduces natural killer cells in mice. J Immunol 1978;121:2193-8.
177. Ratajczak HV, Sothern RB, Hrushesky JM. Estrous influence on surgical care of a mouse breast cancer. J Exp Med 1988;168:73-83.
178. Hrushesky WJM, Gruber SA, Sothern RB, Hoffman RA, Lakatua D, Carlson A, et al. Natural killer cell activity: Age, estrous and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst 1988;80:1232-7.
179. Thyss A, Caldani C, Bourcier C, Benita G, Schneider M. Comparison of natural killer activity during the first and second halves of the menstrual cycle in women [letter]. Br J Cancer 1984;50:127-8.
180. Sulke AN, Jones DB, Wood PJ. Variation in natural killer activity in peripheral Wood during the menstrual cycle. BMJ (Clin-Res-Ed) 1985;290:884-6.
181. Holbrook NJ, Cod WI, Horner HC. Direct suppression of natural killer activity in human peripheral blood leukocytic cultures by glucocorticoids and its modulation by interferon. Cancer Res 1983;43:4019-25.
182. Sulke AN, Jones DB. Hormonal modulation of human natural killer (NK) activity. J Reprod Immunol 1985;7:105-10.
183. Baley JE, Schacter BZ. Mechanisms of diminished natural killer cell activity in pregnant women and neonates. J Immunol 1985;134:3042-8.
184. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991;337:1261-4.
185. McGuire WL, Hilsenberg S, Clark GM. Optimal mastectomy timing. J Natl Cancer Inst 1992;84:346-8.
186. Early breast cancer trialist collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy [original papers]. Lancet 1992;339:71-85.
187. Mallmarn P, Krebs D. Effects of tamoxifen on parameters of cell-mediated immunity on postmenopausal patients with breast cancer. Zentralbl Gynakol 1991;113:685-9.
188. Mandeville R, Ghali SS, Chausseau JP. In vitro stimulation of human NK activity by an oestrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 1984;20:983-5.
189. Berry J, Green BJ, Matheson DS. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 1987;23:517-20.
190. Onsurd M, Thorsby E. Long term changes in natural killer cytotoxicity after external pelvic radiotherapy. Int J Radiat Oncol Biol Phys 1981;7:609-14.
191. Hochman PS, Cudkowicz G, Dausset J. Decline of natural killer cell activity in sublethally irradiated mice. J Natl Cancer Inst 1978;61:265-8.
192. Gorelick E, Herberman RB. Depression of natural antitumor resistance of C57BL/6 mice be leukomegenic doses of radiation and restoration of resistance by transfer of bone marrow or spleen cells from normal, but not beige, synergenic mice. J Natl Cancer Inst 1982;69:89-93.
193. Ruysscher DD, Waer M, Vandeputte M, Van der Scheurren E. Immunologic changes after loco-regional radiotherapy and fractionated total body irradiation (TBI) in mice. Int J Radiat Oncol Biol Phys 1989;17:1237-45.
194. Yamaue H, Tanimura H, Aoki Y, Tsunodfa T, Iwahashi M, Tani M. Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer. J Surg Oncol 1992;49:10-5.
195. Blomgren H, Baral E, Esmyr F, Strender L-E, Petrini B, Wasserman J. Natural killer activity in peripheral lymphocyte population following local radiation therapy. Acta Radiol Oncol 1980;19:139-43.
196. Petrini B, Wasserman J, Blomgren H. T-cell subsets in patients treated with pelvic irradiation for cancer. J Clin Lab Immunol 1985;17:147-8.
197. Manderville R, Sidrac-Ghali S, Ajdukovic I, Vidai D, Ayoub J. Early inhibition of natural and interferon-activated killers in endometrial cancer patients treated with local radiotherapy. Cancer Detect Prev 1987;10:129-39.
198. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response. II. Cancer Invest 1985;3:23-33.
199. Ehrke MJ. Effect of cancer therapy on host response and immunobiology. Curr Science 1991;3:1070-7.
200. Schoof DD, Massaro AF, Obando IA, Kusack JC, Eberlein TJ. The biological effects of immunosuppression on cellular immunotherapy. Surg Oncol 1992;1:27-35.
201. Mastino A, Greli S, Premrov MG, Favalli C. Susceptibility of influenza A virus infection in mice immunosuppressed with cyclophosphamide. J Chemother 1991;3:156-61.
202. Eremin O, Sewell H. The immunological basis of surgical science and practice. New York: Oxford University Press: 1992:145-158.
203. De Vecchis L, Pastore S, Migliorati G, Bonmassar Giuliani A, Frati L. Amplification of natural killer activity of mouse lymphocytes by vincristine. Int J Tissue React 1982;4:283-9.
204. Charmella LJ, Meyer C, Thompson GE, Dimitrov NV. Chemotherapeutic agents and modulation in natural killer cell activity in vitro. J Immunopath 1985;7:53-65.
205. Ujhazy P, Babusikova O. NK-cell activity affected by some cytostatic drugs and their additives. Neoplasma 1991; 38:303-12.
206. Wasik M, Rychlik G, Gorski A. The effect of cyclophosphamide derivatives on cellular cytotoxicity (NK, ADCC) in vitro. Arch Immunol Ther Exp (Warsz) 1990;38:259-65.
207. Brenner BG, Gryllis C, Gomitsky M, Cupples W, Wainberg M. Differential effects of chemotherapy-induced and HIV-1-Induced immunocompromise on NK and LAK cell activities using breast cancer and HIV-1 seropositive patient populations. Anticancer Res 1991;11:969-974.
208. Bonilla A, Alvarez-Mon M, Merino F, Giron JA, Menendez JL, Espana P, et al. Natural killer activity in patients with breast cancer. Eur J Gynaecol Oncol 1990;11:103-9.
209. Sewell HF, Halbert CF, Robins RA, Calvin A, Chan S, Blarney RW, et al. Chemotherapy-induced differential changes in lymphocyte subsets and natural killer cell function in patients with advanced breast cancer. Int J Cancer 1993; 55:735-8.
210. Brittenden J, Heys SD, Ross J, Park KGM, Eremin O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. Eur J Surg Oncol 1994;20:467-72.
211. Garzetti GG, Ciavattini A, Provincali M, Valensise H, Romanini C, Fabris N. Influence of neoadjuvant polychemotherapy on natural killer cell activity in patients with locally advanced cervical squamous carcinoma. Gynecol Oncol 1994;52:39-43.
212. Braun DP, Harris JE. Effect of chemotherapy on NK function in the peripheral blood of cancer patients. Cancer Immunol Immunother 1986;21:240-5.
213. Saijo N, Shimizu E, Shibuya M, Irimajiri N, Takizawa T, Eguchi J, et al. Effects of chemotherapy on natural killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. Br J Cancer 1982;46:180-9.
214. Hong W-S, Kim C-M, Lee J-O, Kang T-W, Yun T-K. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriarnycin and mitomycin-C chemotherapy. Jpn J Clin Oncol 1990;20:87-93.
215. Ondera H, Someis SS, Guillou PJ. Paradoxical effects of 5-FU/folinic acid on lymphokine activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer 1990;62:1042-6.
216. Nakuri T, Ueno Y, Ueno Y, Koizumi S. Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate. Cancer Immunol Immunother 1990;32:8-12.
217. Katsanis E, Bausero MA, Ochoa AC, Loeffler CM, Blazer BR, Leonard AS, et al. Importance of timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cancer Immunol Immunother 1990;34:74-8.
218. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994;134:223-33.
219. Savas R, Cole SP, Akoglu TP, Pross HF. P-glycoprotein mediated multidrug resistance and cytotoxic effector cells. Nat Immun 1992;11:177-92.
220. Eberlein TJ, Rosentstein M, Rosenberg SA. Regression of a disseminated syngenic solid rumor by systemic transfer of lymphoid cells expanded in interleukin-2. J Exp Med 1982;156:385-97.
221. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976;193:1007-8.
222. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982;155:968-80.
223. Donohue JH, Rosenstein M, Chang A, Lotze MT, Robb RJ, Rosenberg SA. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngenic lymphoma. J Immunol 1984;132:2123-8.
224. Rosenberg SA, Mule JJ, Speiss PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin 2. J Exp Med 1985; 161:1169-88.
225. Rosenberg SA, Lotze MT, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
226. Kolitz JE, Mertelsman R. The immunotherapy of human cancer with interleukin 2: Present status and future directions. Cancer Invest 1991;9:529-42.
227. Heys SD, Franks CR, Eremin O. Interleukin-2 therapy: current role in surgical oncological practice [review], Br J Surg 80:155-162.
228. Jones M, Philip T, Palmer P, Von der Masse H, Vinke J, Elson P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-88.
229. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;9:183-209.
230. Heys SD, Deehan DJ, Eremin O. Interleukin 2 treatment in colorectal cancer: current results and future prospects. Eur J Surg Oncol 1994;20:622-9.
231. Rosenberg SA, Mule JJ, Speiss PJ, Reichart CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161:1169-88.
232. Lafrenier R, Rosenberg SA. Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 1985;45:3735-41.
233. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Ghang AE, Ettinghausen SE. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
234. Williams TM, Fox KR, Kant JA. Interleukin-2: Basic biology and therapeutic use. Hematol Pathol 1991;5:45-55.
235. West WH, Kurt W, Tauer KW, Yannelli JR, Marshall GD, Orr DW, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:5947-52.
236. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;2:622-32.
237. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994; 86:1159-66.
238. Takaku F. Clinical application of cytokines for cancer treatment [review]. Oncology 1994;51:123-8.
239. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP, et al. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer 1995;76:1253-61.
240. Hill ADK, Redmond HP, Croke DT, Grace PA, Bouchier-Hayes D. Cytokines in tumor therapy. Br J Surg 1992;79:990-7.
241. Lange W, Brugger W, Rosenthal FM, Kanz L, Linderman A. The role of cytokines in oncology. Int J Cell Cloning 1991;9:252-73.
242. Rosenberg SA, Lotze MT, Yang JC, Lineham WM, Seipp C, Karp SE. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
243. Atzopodien J, Kirchner H, de Mulder P, Bodenstein H, Oliver T, Palmer PA, et al. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter phase II study. Cancer Biother 1993;8:289-300.
244. Atzpodien J, Kirchner H, Korfer A, Hadam M, Schomburg A, Menzel T, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol 1993;14:354-9.
245. Oppenheim MH, Lotze MT. Interleukin-2: a solid tumor therapy [review]. Oncology 1994;51:154-69.
246. Atzopodien J, Kirchner H, Harminen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastaic renal cell cancer. Eur J Cancer 1993;29A:6S-8S.
247. Robinet E, Kamoun M, Farace F, Chouaib S. Interleukin-4 differentially regulates interieukin-2-mediated and CD2-mediated induction of human lymphokine-activated killer effectors. Eur J Immunol 1992;22:2861-5.
248. Bosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 1994;5:447-52.
249. Mule JJ, Custer MD, Travis WD, Rosenberg SA. Cellular mechanism of the anti-tumour activity of recombinant IL-6 in mice. J Immunol 1992;148:2622-9.
250. Gallacher G, Stimson WH, Findlay J, Al-Azzawi F. Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immuno Immunother 1990;31:49-56.
251. Mule JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Clinical application of IL-6 in cancer therapy. Res Immunol 1992;143:777-9.
252. van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994;84:1431-41.
253. Stotter H, Lotze MT. Human lymphokine-activated killer cell activity; role of IL-2, IL-4 and IL-7. Arch Surg 1991;126:1525-30.
254. Dadmarz R, Bockstoce DC, Golub SH. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56 bright natural killer subpopulation. Lymphokine and cytokine. Research 1994;13:349-57.
255. Bohm M, Moller P, Kalbfleisch U, Worm M, Czarnetzki BM, Schadendorf D. Lysis of allogenic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. Br J Cancer 1994;70:54-9.
256. Spagnoli GC, Juretic A, Schulz-Thater E, Dellabona P, Filgueira L, Hong H, et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine activated killer cell activity. Cell Immunol 1993;46:391-405.
257. Brunda MJ, Luistro L, Warrier RB, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30.
258. Lieberman MD, Sigal RK, Williams NN, Daly JM. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J Surg Res 1991;50:410-5.
259. Andrews JVF, Schhof DD, Bertagnolli MM, People GE, Goedegebuure PS, Eberlein TJ. Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J Immunother 1993;14:1-10.
260. Linderman A, Hoeffken K, Schmidt RE, Diehl V, Kloke O, Ganm H, et al. A phase II study of low-dose-cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989;28:275-81.
261. Freund M, Von Wussow P, Diedrich H. Recombinant human interferon (IFN) alpha-2b in chronic myelogeneous leukemia: dose dependency of response and frequency of neutralizing antibodies. Br J Haematol 1989;72:350-6.
262. Scharenberg JGM, Stam AGM, von Blomberg BME, Roest GJ, Palmer PA, Franks CR, et al. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur J Cancer 1994;30(A):1804-9.
263. Oliver RTD. New views on rejection mechanisms and their relevance to interleukin-2 (rIL-2) influences the proliferation of G-361 human melanoma cells in culture. Eur J Cancer 1991;27:1172-7.
264. McMillan DN, Kernohan N, Heys SD, Eremin O. Human recombinant interleukin-2 (rIL-2) influences the proliferation of G-361 human melanoma cells in culture. Br J Cancer 1993;(suppl XX)67:51.
265. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WG. Receptors for interleukin 2 on human squamous cell lines and tumor in situ. Cancer Res 1992;52:5963-70.
266. Rosenberg SA. Immunotherapy and gene therapy of cancer [review]. Cancer Res 1991;18 Suppl;51:5074S-9S.